(VIANEWS) – Shares of Horizon Therapeutics (NASDAQ: HZNP) slid by a staggering 15.69% to $94.64 at 11:22 EST on Tuesday, after two sequential sessions in a row of gains. NASDAQ is jumping 0.17% to $12,386.53, following the last session’s upward trend. This seems, up to now, a somewhat bullish trend exchanging session today.
Horizon Therapeutics’s last close was $112.25, 1.39% below its 52-week high of $113.83.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, Horizon Therapeutics has a trailing twelve months EPS of $1.59.
PE Ratio
Horizon Therapeutics has a trailing twelve months price to earnings ratio of 59.52. Meaning, the purchaser of the share is investing $59.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.5%.
More news about Horizon Therapeutics (HZNP).
